View More View Less
  • 1 Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyków 18, PL 40752, Katowice, Poland
Restricted access

Summary

Ezetimibe is the first in a new class of antihypercholesterolemic drugs. Since it has not long been available on the market, many of its properties may still be revealed. Analytical methods for its determination are scarce, especially regarding serum samples. A simple, fast, and effective high-performance liquid chromatography-ultraviolet (HPLC-UV) method for the determination of ezetimibe concentration in human serum has therefore been developed. Three mobile phases were analysed, and original modifications to the concentration and flow parameters were made. Of five potential internal standards (IS), only nitrendipine was found to be suitable. The analytical wavelength was chosen based on the absorption spectrum of ezetimibe in the mobile phase. Finally, an extraction analysis was performed using two different solvents, and the extrahent volume was optimised. The final method developed was as follows. Single extraction of 1 mL serum sample, spiked with IS, was performed using 10 mL of methyl-t-butyl ether. Separation was obtained at ambient temperature on a Waters C18 Symmetry Shield (4.6 mm × 250 mm, 5 μm) column. The isocratic mobile phase was composed of acetonitrile and 0.1 M ammonium acetate aqueous solution 55:45 (v/v), set at flow rate of 0.75 mL min−1. Ezetimibe was detected at a wavelength of 232 nm after 5.49 min, and the IS was detected at 8.05 min. The developed method has been validated according to ICH standards. It was found to be specific, precise, accurate and linear over the range 10–800 ng mL−1 with R2 > 0.998, and detection and quantification limits of 4.60 ng mL−1 and 13.94 ng mL−1, respectively. The method has been applied to clinical serum samples. The developed technique allowed for successful in vivo assessment of ezetimibe concentrations in samples obtained from hypercholesterolemia patients who are chronically receiving the drug.

  • [1]. L. Jeu J.W. Cheng 2003 Clin. Ther. 25 2352.

  • [2]. M. Garcia-Calvo J. Lisnock H.G. Bull B.E. Hawes D.A. Burnett M.P. Braun J.H. Crona H.R. Davis Jr. D.C. Dean P.A. Detmers M.P. Graziano M. Hughes D.E. Macintyre A. Ogawa K.A. O'neill S.P. Iyer D.E. Shevell M.M. Smith Y.S. Tang A.M. Makarewicz F. Ujjainwalla S.W. Altmann K.T. Chapman N.A. Thornberry 2005 Proc. Natl. Acad. Sci. USA 102 8132.

    • Search Google Scholar
    • Export Citation
  • [3]. H.M. Lotfy A.M. Aboul Alamein M.A. Hegazy 2010 J. AOAC Int. 93 1844.

  • [4]. S.J. Varghese T.K. Ravi 2010 J. AOAC Int. 93 1222.

  • [5]. G. Bahrami B. Mohammadi P.M. Khatabi M.H. Farzaei M.B. Majnooni S.R. Bahoosh 2010 J. Chromatogr. B 878 2789.

  • [6]. R. Sistla V.S. Tata Y.V. Kashyap D. Chandrasekar P.V. Diwan 2005 J. Pharm. Biomed. Anal. 39 517.

  • [7]. S.J. Basha S.A. Naveed N.K. Tiwari D. Shashikumar S. Muzeeb T.R. Kumar N.V. Kumar N.P. Rao N. Srinivas R. Mullangi N.R. Srinivas 2007 J. Chromatogr. B 853 88.

    • Search Google Scholar
    • Export Citation
  • [8]. J.E. Patrick T. Kosoglou K.L. Stauber K.B. Alton S.E. Maxwell Y. Zhu P. Statkevich R. Iannucci S. Chowdhury M. Affrime M.N. Cayen 2002 Drug Metab. Dispos. 30 430.

    • Search Google Scholar
    • Export Citation
  • [9]. M. Hefnawy M. Al-Omar S. Julkhuf 2009 J. Pharm. Biomed. Anal. 50 527.

  • [10]. R.P. Dixit C.R. Barhate S.G. Padhye C.L. Viswanathan M.S. Nagarsenker 2010 Indian J. Pharm. Sci. 72 204.

  • [11]. T. Kosoglou P. Statkevich A.O. Johnson-Levonas J.F. Paolini A.J. Bergman K.B. Alton 2005 Clin. Pharmacokinet. 44 467.

  • [12]. F.J. Al Badarin I.J. Kullo S.L. Kopecky R.J. Thomas 2009 Mayo Clin. Proc. 84 353.

  • [13]. U. Seedorf T. Engel A. Lueken G. Bode S. Lorkowski G. Assmann 2004 Biochem. Biophys. Res. Commun. 320 1337.

  • [14]. S.M. Shaw O. Najam U. Khan N. Yonan S.G. Williams J.E. Fildes 2009 Transpl. Immunol. 21 179.

  • [15]. E. Orsó T. Werner Z. Wolf S. Bandulik W. Kramer G. Schmitz 2006 Cytometry A 69 206.

  • [16]. ICH Expert Working Group, in: ICH Harmonised Triptate Guideline, Geneva, 2005, p. 1.

  • [17]. K. Łabuzek D. Suchy B. Gabryel A. Bielecka S. Liber B. Okopień 2010 Pharmacol. Rep. 62 956.

  • [18]. A.A. Kadav D.N. Vora 2008 J. Pharm. Biomed. Anal. 48 120.

  • [19]. I. Niopas A.C. Daftsios 2003 J. Pharm. Biomed. Anal. 32 1213.

  • [20]. B.G. Chaudhari N.M. Patel P.B. Shah L.J. Patel V.P. Patel 2007 J. AOAC Int. 90 1539.

  • [21]. S. Oswald E. Scheuch I. Cascorbi W. Siegmund 2006 J. Chromatogr. B 830 143.

  • [22]. S. Li G. Liu J. Jia X. Li C. Yu 2006 J. Pharm. Biomed. Anal. 40 987.

  • [23]. C. Simard J. Turgeon 2003 Can. J. Clin. Pharmacol. 10SupplA 13A.

  • [24]. A.K. Gajjar V.D. Shah 2011 J. Pharm. Biomed. Anal. 55 225.

  • [25]. F. Ezzet G. Krishna D.B. Wexler P. Statkevich T. Kosoglou V.K. Batra 2001 Clin. Ther. 23 871.

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jul 2020 3 2 0
Aug 2020 1 0 0
Sep 2020 4 0 0
Oct 2020 10 0 0
Nov 2020 5 0 0
Dec 2020 0 0 0
Jan 2021 1 0 0